Compare BMRC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMRC | BWAY |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.4M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | BMRC | BWAY |
|---|---|---|
| Price | $27.59 | $16.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $28.00 | $23.50 |
| AVG Volume (30 Days) | ★ 93.0K | 61.3K |
| Earning Date | 01-26-2026 | 11-11-2025 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | ★ 0.62 | 0.13 |
| Revenue | ★ $96,957,000.00 | $49,094,000.00 |
| Revenue This Year | $63.10 | $330.76 |
| Revenue Next Year | $15.24 | $22.24 |
| P/E Ratio | ★ $44.99 | $53.28 |
| Revenue Growth | ★ 63.31 | 27.08 |
| 52 Week Low | $19.14 | $7.84 |
| 52 Week High | $28.48 | $18.18 |
| Indicator | BMRC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 46.21 |
| Support Level | $26.52 | $16.75 |
| Resistance Level | $28.21 | $17.38 |
| Average True Range (ATR) | 0.65 | 0.75 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 54.08 | 21.06 |
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.